MBX Biosciences (MBX) Enterprise Value (2023 - 2026)
MBX Biosciences (MBX) reported Enterprise Value of -$440.0 million for Q1 2026, down 82.73% on a YoY basis from -$2.5 billion in Q1 2025, and down 17.73% sequentially from -$373.7 million in Q4 2025.
MBX Biosciences (MBX) Enterprise Value (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Enterprise Value data on file, last reported at -$440.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 82.73% year-over-year to -$440.0 million; the trailing twelve-month figure through Mar 2026 stood at -$440.0 million (down 82.73% YoY), and the FY2025 full-year result was -$373.7 million, down 42.55% from the prior year.
- Enterprise Value slipped to -$440.0 million in Q1 2026, from -$373.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $115.9 million in Q2 2024 to a low of -$440.0 million in Q1 2026.
- A 4-year average of -$187.8 million and a median of -$240.8 million in 2025 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value slumped 859.06% in 2024 and slumped 41.37% in 2025, its largest moves.
- Tracing MBX's Enterprise Value over 4 years: stood at -$44.2 million in 2023, then tumbled by 493.43% to -$262.1 million in 2024, then plunged by 42.55% to -$373.7 million in 2025, then dropped by 17.73% to -$440.0 million in 2026.
- Business Quant data shows MBX's Enterprise Value at -$440.0 million in Q1 2026, -$373.7 million in Q4 2025, and -$391.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | -439.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -439.98 Mn |
| Dec 31, 2025 | -373.71 Mn |
| Sep 30, 2025 | -391.67 Mn |
| Jun 30, 2025 | -224.91 Mn |
| Mar 31, 2025 | -240.79 Mn |
| Dec 31, 2024 | -262.15 Mn |
| Sep 30, 2024 | -277.06 Mn |
| Jun 30, 2024 | 115.86 Mn |
| Mar 31, 2024 | 36.50 Mn |
| Dec 31, 2023 | -44.18 Mn |
| Sep 30, 2023 | 36.50 Mn |